سعر كالكوينس 100 مجم 60 كبسولة 2024

Calquence (acalabrutinib) 100 mg capsules, 60 count (AstraZeneca). Prescription oncology medicine.

• Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).Population: AdultsDailyMed / FDA USPI
• Mantle cell lymphoma: previously untreated (with bendamustine+rituximab if autologous HSCT-ineligible); previously treated after ≥1 prior therapy.Population: Adults with MCLDailyMed / FDA USPI

• Most common adverse reactions (≥30%, excluding labs): upper respiratory tract infection, diarrhea, headache, musculoskeletal pain. Common Grade 3/4 labs: decreased ANC, increased uric acid, decreased ALC, decreased platelets.International label, same product · DailyMed / FDA USPI

• USPI lists no contraindications (section 4).International label, same product · DailyMed / FDA USPI

• Serious and opportunistic infections (including fatal) have occurred; monitor and treat promptly; consider prophylaxis in high-risk patients.International label, same product · DailyMed / FDA USPI
• Fatal and serious hemorrhage; risk may increase with antithrombotics; consider holding 3–7 days around surgery.International label, same product · DailyMed / FDA USPI
• Grade 3/4 cytopenias (neutropenia, anemia, thrombocytopenia); monitor CBCs regularly.International label, same product · DailyMed / FDA USPI

• Strong CYP3A inhibitorsMajorAvoid co-administration; if short-term use unavoidable, interrupt Calquence and resume after inhibitor stopped ≥24 h.DailyMed / FDA USPI
• Strong CYP3A inducersMajorAvoid co-administration; if unavoidable, increase Calquence to 200 mg approximately every 12 hours.DailyMed / FDA USPI
• Proton pump inhibitorsModerateAvoid concomitant PPIs (acid suppression reduces acalabrutinib exposure for capsules).DailyMed / FDA USPI

• Based on animal data, may cause fetal harm and dystocia; no adequate human pregnancy data. Advise of potential fetal risk.International label, same product · DailyMed / FDA USPI
• Advise lactating women not to breastfeed during treatment and for at least 2 weeks after the final dose.International label, same product · DailyMed / FDA USPI

• Acalabrutinib: Covalent BTK inhibitor; blocks BCR signaling needed for malignant B-cell proliferation.